At the end of their cycle, hematocrit stages had amplified by three%-stage when compared with baseline. The rise wasn't connected to lengthier use or greater AAS dose. A basis for this is likely to be that, further than a specific standard of androgenic action, no more enhance of hematocrit occurs: a ‘ceiling result’. Notably, Whilst only 5% of